A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
Completed · Phase 2 · NCT02880956
Conditions: Alzheimer's Disease
At a glance
- Research payments reported, 2025
- $17,475
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 453
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-8E12 (drug), placebo for ABBV-8E12 (drug)
- Dates
- Started 2017-01-26; completion 2021-07-28
- Results posted
- Yes
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
From ClinicalTrials.gov, last updated 2022-08-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $17,475 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of South Florida $15,347
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $2,128
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.